Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks

European Journal of Pharmaceutical Sciences

Volumn 33, Issue 1, 2008, Pages 80-90

  de Matas, Marcel ^a   Shao, Qun ^a   Richardson, Catherine H ^a   Chrystyn, Henry ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Artificial neural networks; Bronchodilator response; Dry powder inhalers; In vitro in vivo correlation; Relative lung bioavailability

Indexed keywords

ASMASAL; DRUG METABOLITE; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ARTIFICIAL NEURAL NETWORK; ASTHMA; BODY SURFACE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG URINE LEVEL; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG; LUNG FUNCTION; MALE; POWDER INHALER; PRIORITY JOURNAL; URINARY EXCRETION;

ADMINISTRATION, INHALATION; ADULT; ALBUTEROL; ALGORITHMS; ASTHMA; BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; NEURAL NETWORKS (COMPUTER); PARTICLE SIZE; PEAK EXPIRATORY FLOW RATE; POWDERS; SEVERITY OF ILLNESS INDEX; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 36849030787     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2007.10.001     Document Type: Article

References (31)

1. Bourquin J., Schmidli H., Hoogevest P.V., and Leuenberger H. Application of artificial neural networks (ANN) in the development of solid dosage forms. Pharm. Dev. Technol. 2 (1997) 111-121
2. Cheng Y.S., Yazzie D., Gao J., Muggli D., Etter J., and Rosenthal G.J. Particle characteristics and lung deposition patterns in a human airway replica of a dry powder formulation of polylactic acid produced using supercritical fluid technology. J. Aerosol Med. 16 (2003) 65-73
3. Chrystyn H. Standards for bioequivalence for inhaled products. Clin. Pharmacokinet. 26 1 (1994) 1-6
4. de Matas M., Shao Q., Silkstone V.L., and Chrystyn H. Evaluation of an in-vitro in-vivo correlation for nebuliser delivery using artificial neural networks. J. Pharm. Sci. 96 (2007) 3293-3303
5. Dowell J.A., Hussain A., Devane J., and Young D. Artificial neural networks applied to the in vitro in vivo correlation of an extended-release formulation: initial trials and experience. J. Pharm. Sci. 88 1 (1999) 154-160
6. Emami J. In-vitro in-vivo correlation: from theory to applications. J. Pharm. Pharmaceut. Sci. 9 2 (2006) 169-189
7. FDA, 1997. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations.
8. Feddah M.R., Brown K.F., Gipps E.M., and Davies N.M. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J. Pharm. Pharmaceut. Sci. 3 3 (2000) 317-324
9. Hindle M., and Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br. J. Clin. Pharmacol. 34 (1992) 311-315
10. Leach C.L., Davidson P.J., Hasselquist B.E., and Boudreau R.J. Influence of particle size and patient dosing technique on lung deposition of HFA-Bechlomethasone from a metered dose inhaler. J. Aerosol Med. 18 (2005) 379-385
11. Lipworth B.J., and Clark D.J. Effect of airway calibre on lung delivery of nebulised salbutamol. Thorax 52 (1997) 1036-1039
12. Nazir J., Barlow D.J., Lawrence M.J., Richardson C.J., and Shrubb I. Artificial neural network prediction of aerosol deposition in human lungs. Pharm. Res. 19 8 (2002) 1130-1136
13. Nazir J., Lawrence M.J., and Shrubb I. Artificial neural network prediction of the patterns of deposition of polydisperse aerosols within human lungs. J. Pharm. Sci. 94 9 (2005) 1986-1997
14. Newman S.P., Pitcairn G.R., Hirst P.H., Bacon R.E., O'Keefe E., Reiners M., and Hermann R. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur. Respir. J. 16 1 (2000) 178-183
15. Nielsen K.G., Skov M., Klug B., Ifversen M., and Bisgaard H. Flow-dependent effect of formoterol dry-powder inhaler from the aerolizer. Eur. Respir. J. 10 9 (1997) 2105-2109
16. Niu T., Rogus J.J., Chen C., Wang B., Yang J., Fang Z., Weiss S.T., and Xu X. Familial aggregation of bronchodilator response: a community-based study. Am. J. Respir. Crit. Care Med. 162 5 (2000) 1833-1837
17. Pilcer G., Sebti T., and Amighi K. Formulation and characterisation of lipid-coated Tobramycin particles for dry powder inhalation. Pharm. Res. 23 (2006) 931-940
18. Pritchard J.N. The influence of lung deposition on clinical response. J. Aerosol Med. 14 Suppl. 1 (2001) S19-S26
19. Richardson, C.H., de Matas, M., Hosker, H., Mukherjee, R., Wong, I., Chrystyn, H., 2007. Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization. Pharm. Res. Published on-line, May 2007.
20. Roth A.P., Lange C.F., and Finlay W.H. The effect of breathing pattern on nebulizer drug delivery. J. Aerosol Med. 16 (2003) 325-339
21. Rowe R.C., and Roberts R.J. Intelligent Software for Product Formulation (1998), Taylor and Francis, London, UK
22. Shao Q., Rowe R.C., and York P. Comparison of neurofuzzy logic and neural networks in modelling experimental data of an immediate release tablet formulation. Eur. J. Pharm. Sci. 28 5 (2006) 394-404
23. Silkstone V.L., Dennis J.H., Pieron C.A., and Chrystyn H. An investigation of in vitro/in vivo correlations for salbutamol nebulized by eight systems. J. Aerosol Med. 15 3 (2002) 251-259
24. Srichana T., Suedee R., Muanpanarai D., and Tanmanee N. The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. J. Pharm. Sci. 94 1 (2005) 220-230
25. Stuart B.O. Deposition of inhaled aerosols. Arch. Intern. Med. 131 (1973) 60-73
26. Svartengren M., Falk R., Linnman L., Philipson K., and Canner P. Deposition of large particles in human lung. Exp. Lung Res. 12 1 (1987) 75-88
27. Ullah M.I., Newman G.B., and Saunders K.B. Influence of age on response to ipratropium and salbutamol in asthma. Thorax 36 (1981) 523-529
28. Usmani O.S., Biddiscombe M.F., and Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am. J. Respir. Crit. Care Med. 172 (2005) 1497-1504
29. Vanto T., Hamalainen K.M., Vahteristo M., Wille S., Nja F., and Hyldebrandt N. Comparison of two budesonide dry powder inhalers in the treatment of asthma in children. J. Aerosol Med. 17 (2004) 15-24
30. Varsha C., and Dalby R. Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory airflow on fine particle output from a dry powder inhaler. Pharm. Sci. 4 2 (2002) (online computer file)
31. Zanen P., Go L.T., and Lammers J.W.J. Optimal particle size for beta-2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 51 (1996) 977-980